BioXcel Therapeutics, Inc. financial data

Symbol
BTAI on Nasdaq
Location
555 Long Wharf Drive, New Haven, CT
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 252 % -60.3%
Quick Ratio 7.28 % +19.9%
Debt-to-equity -232 % -220%
Return On Equity 177 %
Return On Assets -134 % -27.2%
Operating Margin -4.56K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 40.7M shares +39.2%
Common Stock, Shares, Outstanding 40.4M shares +38%
Entity Public Float 135M USD -46.2%
Common Stock, Value, Issued 40K USD +37.9%
Weighted Average Number of Shares Outstanding, Basic 40.3M shares +37.9%
Weighted Average Number of Shares Outstanding, Diluted 40.3M shares +37.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.4M USD +142%
Research and Development Expense 49M USD -55.3%
General and Administrative Expense 55.5M USD +66.6%
Costs and Expenses 112M USD -43%
Operating Income (Loss) -110M USD +43.9%
Nonoperating Income (Expense) 62K USD
Net Income (Loss) Attributable to Parent -108M USD +46.9%
Earnings Per Share, Basic -3.56 USD/shares +50%
Earnings Per Share, Diluted -3.56 USD/shares +50%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 56.3M USD -55.9%
Inventory, Net 2.68M USD +39.2%
Other Assets, Current 1.64M USD -64.6%
Assets, Current 64.2M USD -53.6%
Property, Plant and Equipment, Net 629K USD -33.2%
Operating Lease, Right-of-Use Asset 538K USD -35.5%
Other Assets, Noncurrent 87K USD 0%
Assets 65.4M USD -53.3%
Accounts Payable, Current 13.3M USD +18.3%
Employee-related Liabilities, Current 2.08M USD -48.4%
Accrued Liabilities, Current 13.5M USD -29.5%
Liabilities, Current 27.3M USD -21.5%
Operating Lease, Liability, Noncurrent 256K USD -58.5%
Liabilities 140M USD +4.1%
Retained Earnings (Accumulated Deficit) -626M USD -20.8%
Stockholders' Equity Attributable to Parent -74.3M USD -1367%
Liabilities and Equity 65.4M USD -53.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.7M USD +66.2%
Net Cash Provided by (Used in) Financing Activities 26.6M USD +10.3%
Net Cash Provided by (Used in) Investing Activities -120K USD +62%
Common Stock, Shares Authorized 200M shares +100%
Common Stock, Shares, Issued 40.4M shares +38%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8.92M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 56.3M USD -55.9%
Deferred Tax Assets, Valuation Allowance 174M USD +46.7%
Operating Lease, Liability 617K USD -35%
Depreciation 312K USD -4.59%
Payments to Acquire Property, Plant, and Equipment 120K USD -62%
Lessee, Operating Lease, Liability, to be Paid 647K USD -36.8%
Property, Plant and Equipment, Gross 1.98M USD 0%
Operating Lease, Liability, Current 361K USD +8.74%
Lessee, Operating Lease, Liability, to be Paid, Year Two 65K USD -83.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 391K USD +2.63%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 30K USD -60%
Lessee, Operating Lease, Liability, to be Paid, Year Three 65K USD -83.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 65K USD -83.4%
Additional Paid in Capital 551M USD +5.28%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 309K USD +50%
Deferred Tax Assets, Net of Valuation Allowance 197K USD -23%
Share-based Payment Arrangement, Expense 12.1M USD -39.6%
Interest Expense 13.6M USD +17.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%